PD-L1 (TAP) >= 5%
About
Biomarker Type: Protein expression
Present: True
Marker: PD-L1
Unit: Tumor Area Positivity (TAP)
Equality: >=
Value: 0.05
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Cisplatin, Fluorouracil, Tislelizumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Capecitabine, Cisplatin, Tislelizumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Fluorouracil, Oxaliplatin, Tislelizumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Capecitabine, Oxaliplatin, Tislelizumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Cisplatin, Paclitaxel, Tislelizumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Oxaliplatin, Paclitaxel, Tislelizumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Adenocarcinoma of the Gastroesophageal Junction | Capecitabine, Oxaliplatin, Tislelizumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Adenocarcinoma of the Gastroesophageal Junction | Cisplatin, Fluorouracil, Tislelizumab |